What Researchers Did
Researchers reviewed various treatment options investigated for radiation-induced optic neuropathy (RON), a severe vision loss complication following radiation therapy.
What They Found
Systemic corticosteroids and anticoagulants showed no benefit for radiation-induced optic neuropathy (RON), while hyperbaric oxygen therapy promoted short-term, partial vision recovery in select patients, especially at partial pressures of at least 2.4 atm. Although systemic bevacizumab has reported vision reversal, its use is limited by side effects such as stroke and myocardial infarction, and intravitreal bevacizumab showed promising results for anterior RON but requires repeated, long-term injections.
What This Means for Canadian Patients
Canadian patients suffering from radiation-induced optic neuropathy currently face limited effective treatment options to prevent or reverse severe, irreversible vision loss. While some therapies like hyperbaric oxygen or intravitral bevacizumab show partial promise, they often require specific conditions or long-term commitment and carry risks, underscoring the need for better interventions.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The primary limitation is the lack of large, controlled prospective studies for most investigated treatments, with current evidence largely derived from small case series.